Document is current

Article History

Received: 29 May 2025

Accepted: 26 August 2025

First Online: 18 September 2025

Declarations

:

: The study was approved by the Research Ethics Committees of participating centers in Spain and the U.S. The study was conducted in full accordance with the principles of the World Medical Association Declaration of Helsinki, the International Conference of Harmonisation, and all applicable local guidelines and regulations on good clinical practice.

: Written informed consent was obtained from all individual patients included in this study.

: All patients provided written informed consent about participation in this study and the use of collated data. No individual patient data are included in this article that could be used to identify any individual.

: A. Falcón reports advisory role for Roche, Pfizer, Menarini, AstraZeneca, and MSD; honoraria from Roche, Pfizer, Novartis, Lilly, Menarini, AstraZeneca, MSD, Daiichi, Gilead, Dr. Reddy, and Grünenthal; and travel accommodations from Novartis, Daiichi, Gilead, and Roche. G.M. Cote reports honoraria from Gilead, and BioAtla; consultant role for Chordoma Foundation, and Sonata Therapeutics; Scientific Advisory Board position for Ikena Oncology, C4 Therapeutics, and Daiichi Sankyo, Inc; Institutional research funding to MGH for the conduct of clinical trials from Servier Pharmaceuticals, Pharma Mar, MacroGenics, Eisai, Merck KGaA/EMD Serono Research and Development Institute, Repare Therapeutics, Foghorn Therapeutics, Jazz Pharmaceuticals, RAIN Oncology, BioAtla, Inhibrx, Ikena Oncology, C4 Therapeutics, Kronos, Bavarian Nordic, and Pyxis; and travel accommodations from Pharma Mar. J.J. Lin reports consulting or advising fees for Genentech, C4 Therapeutics, Blueprint Medicines, Nuvalent, Bayer, Elevation Oncology, Novartis, Mirati Therapeutics, AnHeart Therapeutics, Takeda, CLaiM Therapeutics, Ellipses, AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Yuhan, Merus, Regeneron, Pfizer, Roche, Gilead, Janssen, Nuvation Bio, Eli Lilly, AstraZeneca, Gilead, and Turning Point Therapeutics; institutional research funding from Hengrui Therapeutics, Turning Point Therapeutics, Neon Therapeutics, Relay Therapeutics, Bayer, Elevation Oncology, Roche, Linnaeus Therapeutics, Nuvalent, and Novartis; and travel support from Pfizer, Merus, Takeda, and Bristol Myers Squibb. B. Bockorny reports Research Funding from Agenus Inc and NanoView Bioscience; travel expenses from Erytech Pharma; Advisory Board and Consulting from SpringWorks, Blueprint Medicines, BioLine Rx, Boxer and Enlivex; and institutional research funding to BIDMC for the conduct of clinical trials from Gilead, Pfizer, Novartis, Amgen, Bristol Myers Squibb, Incyte, Eli Lily, Relay, Scholar Rock, OncoMatryx, Pharma Mar, MacroGenics, BioLineRx, AbGenomics, Chugai, and Sapience. J. Martinez reports speakers’ or travel honoraria from MSD, Bristol-Myers and Merck. C. Kahatt and P. Zubiaur are employees and stock owners of Pharma Mar. S. Martinez, M. Siguero, M. Cullell-Young and J. Jiménez are employees of Pharma Mar. J. Zugazagoitia reports speakers’, advisory or travel honoraria from Boehringer Ingelheim, Janssen, Pierre Fabre, Takeda, Sanofi, BMS, AstraZeneca, MSD, Roche, Pfizer, Novartis, and NanoString; and research support/grants from AstraZeneca, Roche, and BMS. L. Paz-Ares reports co-founder position and member of board of directors with Altum Sequencing, and Stab therapeutics; consulting fees or advisory role for Abbvie, Amgen, AstraZeneca, Bayer, Beigene, Biontech, Bristol-Myers-Squibb, Boehringer-Ingelheim, Daiichi-Sankyo, GlaxoSmithKline, Gilead, Johnson & Johnson, Lilly, MSD, Merck-Serono, Mirati, Novartis, Pharma Mar, Pfizer, Regeneron, Roche, Sanofi, and Takeda; speakers’bureau for MSD Oncology, BMS, Roche/Genentech, Pfizer, Lilly, AstraZeneca, and Merck Serono; and institutional research funding from BMS, AstraZeneca, Pharma Mar, MSD, and Pfizer during the conduct of the study.